NCT00599443View on ClinicalTrials.gov

Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years

PHASE1CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 31, 2007

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Healthy
Interventions
BIOLOGICAL

Seasonal cell-derived influenza vaccine

0.5 mL im, single dose

BIOLOGICAL

Placebo Comparator

0.5 mL im, single dose

All Listed Sponsors
lead

Solvay Pharmaceuticals

INDUSTRY

NCT00599443 - Safety and Tolerability of a Cell-Derived Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years | Biotech Hunter | Biotech Hunter